MMI Raises $125M to Expand Robotic Microsurgery and Explore New Treatments

Medical Microinstruments Inc. (MMI) has raised $125 million in Series D financing to expand the reach of its Symani Surgical System and investigate new applications for microsurgery, including an experimental approach to treat Alzheimer’s disease.

The Symani Surgical System is built for microsurgery, unlike many other surgical robots that are designed for larger-scale procedures. The system is intended to help surgeons repair tiny blood and lymphatic vessels during complex procedures, such as those that might follow cancer treatment or trauma. It is also able to be used for peripheral nerve repair in Europe and Asia-Pacific. The device has regulatory clearance in Europe and the U.S. 

The financing, announced earlier this month, comes as the Jacksonville, Florida-based surgical robotics company reported that it has installed approximately 50 systems worldwide, with over 3,500 procedures performed. The new funding will support global commercial expansion for the Symani Surgical System. The funds will also go to improve patient access and advance clinical research to explore additional applications for the technology, according to MMI.

The round’s primary investor was BioStar Capital, a healthcare investment firm headquartered in Naples, FL, with participation from S3 Ventures, Angelini Ventures, and an undisclosed strategic corporate investor, as well as existing investors. 

“We’ve proven there is demand for robotic microsurgery at leading institutions around the world,” said MMI CEO Mark Toland in an announcement. “Now, our focus is translating that adoption into scale.”

The funding will also support research into additional clinical applications, product development in areas such as energy instruments and digital surgery, and the training and infrastructure needed to bring robotic microsurgery into more hospitals. 

“The next phase is about expanding clinical evidence and technology innovation to consistently demonstrate the value of robotic microsurgery and support its integration into clinical practice,” said Toland in an email. “Continued adoption requires not only differentiated, enabling technology, but also strong evidence, effective training programs, growing reimbursement support, and a clear economic benefit for healthcare systems.”

MMI is also exploring whether microsurgical intervention could be used to treat Alzheimer’s disease, a condition affecting 7.4 million Americans aged 65 and older. In May 2026, the company announced that the first patient had undergone a microsurgical procedure intended to address abnormalities in the deep cervical lymph node region as part of its REMIND study, with hopes of improving the symptoms of the patient’s Alzheimer’s disease. In July, MMI received FDA authorization to expand the trial to 15 participants. The company’s website states that this is an “early feasibility study”, with longer-term monitoring and additional testing needed to verify safety and efficacy.

“The long-term opportunity is significant, but expansion into new applications must be led by evidence,” said Toland.

Beyond Alzheimer’s research, Toland said early findings for other applications of the Symani Surgical System have had hopeful results. 

Toland said,“We are encouraged by the growing body of evidence supporting Symani, with promising findings in complex reconstruction applications ranging from flap survival and reduced revisions to lower postoperative pain medication requirements and meaningful limb volume reduction in patients undergoing lymphatic repair.” 

The company says that expanding evidence is its top priority, with next steps including broader, multicenter, and comparative studies to evaluate clinical outcomes and earn additional indication approvals. 

Photo: drogatnev, Getty Images